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sis determines patient eligibility for and the 
potential success of curative treatments. 
Therefore, CT and MRI aided by technologic 
advances that afford improved spatial, tem-
poral, and contrast resolution are regarded as 
promising alternative surveillance tools for 
detecting HCC [4, 5]. Contrast-enhanced dy-
namic multiphasic imaging has substantial 
performance benefits because most HCCs 
are hypervascular lesions that typically be-
come enhanced during the hepatic artery–
dominant phase of imaging [6].
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H
epatocellular carcinoma (HCC) 
accounts for more than 50% of 
deaths related to underlying cir-
rhosis [1]. Although sonography, 
largely because of its relatively low cost and 
ready accessibility, is the most widely used 
technique for HCC screening and surveil-
lance [2], its heavy operator dependence and 
limited depiction of small (< 2 cm in diame-
ter) nodules remain substantial disadvan-
tages [3]. The latter limitation is particularly 
troublesome because tumor stage at diagno-
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OBJECTIVE. The purpose of this study was to retrospectively evaluate the diagnostic 
performance of dynamic gadobenate dimeglumine–enhanced MRI with explant pathologic 
correlation in the detection of hepatocellular carcinoma (HCC) in patients undergoing liver 
transplantation.
MATERIALS AND METHODS. Forty-seven patients (28 men, 19 women; mean age, 
49 years) underwent dynamic gadobenate dimeglumine–enhanced MRI within 3 months be-
fore primary liver transplantation. Dynamic imaging was performed before (unenhanced) 
and after (hepatic arterial, portal venous, equilibrium, and 1-hour delayed phases) IV bolus 
administration of gadobenate dimeglumine at 0.1 mmol/kg body weight. Retrospective image 
analysis to detect HCC nodules was performed independently by two abdominal radiologists 
who had no pathologic information. On a per-nodule basis, the sensitivity and positive predic-
tive value were calculated for the two observers. Sensitivity and specificity in the diagnosis of 
HCC also were evaluated. Fisher’s exact test was performed to determine whether there was 
a detection difference between HCC nodules 1 cm in diameter or larger and nodules smaller 
than 1 cm and to evaluate the differences in causes of false-positive MRI findings based on 
lesion size (≥ 1 cm vs < 1 cm).
RESULTS. Twenty-seven patients had 41 HCCs. In HCC detection, gadobenate dimeglu-
mine–enhanced MRI had a sensitivity of 85% (35 of 41 HCCs) and a positive predictive value 
of 66% (35 of 53 readings) for observer 1 and a sensitivity of 80% (33 of 41 HCCs) and a 
positive predictive value of 65% (34 of 52 readings) for observer 2. For both observers, sensi-
tivity in the detection of HCCs 1 cm in diameter and larger (91–94%) was significantly differ-
ent (p < 0.05) from that in detection of HCCs smaller than 1 cm (29–43%). Nonneoplastic 
arterial hypervascular lesions more often caused false-positive diagnoses of lesions smaller 
than 1 cm in diameter (80–86%) on MR images than of those 1 cm in diameter and larger 
(0–25%). The difference was statistically significant (p < 0.05) for both observers. In diagno-
sis, gadobenate dimeglumine–enhanced MRI had a sensitivity of 87% (20 of 23 patients) and 
a specificity of 79% (19 of 24 patients) for both observers.
CONCLUSION. Dynamic gadobenate dimeglumine–enhanced MRI has a sensitivity 
of 80–85% and a positive predictive value of 65–66% in the detection of HCC. The tech-
nique, however, is of limited value for detecting and characterizing lesions smaller than 1 cm 
in diameter.
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A 3D gradient-echo sequence and parallel 
acquisition techniques facilitate dynamic 
contrast-enhanced imaging of HCC [7–12]. 
Gadobenate dimeglumine has been found 
useful for liver MRI. Because of its weak 
binding with serum albumin, this gadolini-
um-based contrast agent has twofold greater 
T1 relaxivity (9.7 L ⋅ mmol–1 ⋅ s–1 at 0.47 T) 
in human plasma than do other gadolini- 
um-based agents [8, 10, 13–19]. Gadobenate 
dimeglumine is a gadolinium-based para-
magnetic contrast agent that combines the 
properties of a conventional, nonspecific, gad-
olinium-based agent with those of a liver-tar-
geted agent, improving the rate of detection 
of focal hepatic lesions [8, 18, 20]. Because it 
is taken up by functioning hepatocytes and 
excreted in bile, use of gadobenate dimeglu-
mine results in marked and prolonged en-
hancement of normal liver parenchyma for as 
long as 2 hours on T1-weighted images with 
minimal or no enhancement of nonhepatocel-
lular tumors, improving the utility of MRI in 
characterizing focal liver lesions [21–23]. In 
addition, several studies have shown success-
ful use of gadobenate dimeglumine in MR 
angiography of a variety of vascular territo-
ries and in MRI of the brain [24–26].
Previous studies of gadobenate dimeglu-
mine–enhanced MRI have been limited by 
the absence of complete correlation between 
the pathologic and imaging findings. These 
studies have relied on biopsy or surgical re-
section specimens for evaluation of the ac-
curacy of imaging detection and character-
ization of cirrhotic nodules, the resulting 
bias being toward positive study results. Be-
cause some dysplastic nodules [27, 28] and 
lesions of focal nodular hyperplasia [29, 30] 
also become enhanced during the hepatic ar-
terial phase, the presence of arterial phase 
enhancement is not specific for the presence 
of malignancy. In addition, arterial phase en-
hancement can be seen with hemangiomas, 
arterial–portal venous shunts, and aberrant 
venous drainage [31, 32].
To our knowledge, no study of trans-
planted livers has been conducted to evalu-
ate the diagnostic performance of dynamic 
gadobenate dimeglumine–enhanced MRI 
in the detection of HCC. The aim of this 
study was to perform imaging and patho-
logic examinations of liver explants to eval-
uate the diagnostic performance of dynamic 
gadobenate dimeglumine–enhanced MRI 
with a 3D gradient-echo sequence in the de-




Institutional review board approval was obtained 
for retrospective review of patient medical records, 
and informed consent was waived. Between Oc-
tober 2003 and July 2005 at our institution, 113 
patients underwent liver transplantation because of 
cirrhosis. For patients with HCC, the Milan criteria 
were used to determine eligibility for transplan-
tation [33]. Nineteen patients were ex cluded be-
cause they were 18 years old or younger. Eight 
patients who had undergone previous liver trans-
plantation also were excluded. Thirty-nine patients 
were excluded because they had undergone dy-
namic gadobenate dimeglumine–enhanced MRI 
more than 3 months before transplantation (n = 19) 
or had undergone only dynamic liver CT in a 
preoperative evaluation (n = 20). Finally, 47 
consecutively enrolled patients fulfilling the 
following inclusion criteria composed the study 
population: age greater than 18 years, no previous 
liver transplantation, and dynamic gado benate 
dimeglumine–enhanced MRI perform ed no more 
than 3 months before transplantation. Of the 47 
patients, 28 were men and 19 were women. The 
mean age was 49 years (range, 35–62 years). The 
mean time of dynamic gadobenate dime glumine–
enhanced MRI before liver trans plantation was 27 
days (range, 3–78 days). Table 1 sum marizes the 
patient characteristics.
Nine patients in whom HCC was suspected 
because of the features of hypervascular lesions 
on CT or MRI and elevation of α-fetoprotein level 
received the following neoadjuvant treatment 
while awaiting a donor, but the nodules were not 
confirmed with histopathologic examination: 
transcatheter arterial chemoembolization alone in 
seven patients, percutaneous ethanol injection 
alone in one patient, and a combination of these 
two treatments in one patient. These nodules were 
excluded from our analysis. The mean interval 
between treatment and pretransplantation imaging 
was 185 days (range, 90–332 days).
MRI Technique
All MR images of the entire liver were obtained 
with a 1.5-T unit (Sonata, Siemens Medical 
Solutions) with a phased-array torso coil. The 
following sequences for HCC evaluation were 
used in all patients: transverse T2-weighted turbo 
spin-echo sequence without fat saturation (TR/
TE, 2,700/102; flip angle, 150°; echo-train length, 
29; slice thickness, 6 mm), transverse T2-weighted 
HASTE sequence (900/100; flip angle, 150°; 
TABLE 1: Patient Characteristics
Variable All Patients (n = 47)
Patients with Hepatocellular 
Carcinoma (n = 23)
Mean age (y) 49 (range, 35–62) 50 (range, 38–62)
Sex ratio (M/F) 28/19 17/6
Cause of liver disease
Hepatitis B virus 37 20








< 10 25 8
10–100 14 8
101–400 3 3
> 400 5 4
Previous treatment 
Transcatheter arterial chemoembolization 7 7
Percutaneous ethanol injection 1 1
Transcatheter arterial chemoembolization 
plus percutaneous ethanol injection
1 1
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echo-train length, 256; slice thickness, 6 mm), 
transverse T1-weighted gradient-echo in-phase 
(87/5; flip angle, 70°; slice thickness, 6 mm) and 
out-of-phase (87/2.4; flip angle, 70°; slice 
thickness, 6 mm) sequences, and transverse dy-
namic gadobenate dimeglumine–enhanced T1-
weighted volumetric interpolated breath-hold 
examination (VIBE) with fat saturation (3.6/1.7; 
flip angle, 12°; slice thickness, 2.5 mm; matrix 
size, 320 × 170). T1-weighted VIBE images with 
sensitivity-encoding with a reduction factor of 2 
were acquired in a single breath-hold of 18 
seconds. Sensitivity-encoding with a reduction 
factor of 2 was applied in an in-plane phase-
encoding direction in 3D-dynamic imaging be-
tween two directions, that is, the in-plane phase-
encoding direction and the partition direction.
Dynamic imaging was performed before (un-
enhanced) and after (hepatic arterial, portal venous, 
equilibrium, and 1-hour delayed phases) IV bolus 
administration of gadobenate dimeglumine (0.1 
mmol/kg body weight at 2–2.5 mL/s) through a 20- 
to 22-gauge antecubital angiographic venous 
catheter with a power injector (Stellant Dual, 
Siemens Medical Solutions) followed by a 10-mL 
saline flush. The average volume of contrast material 
was 13.2 mL (range, 10.4–15.8 mL). Scanning delay 
times were determined with real-time MRI fluoro-
scopic monitoring after contrast admin istration. 
Acquisition of hepatic arterial phase images was 
started manually at enhancement of the distal 
thoracic aorta. The mean scanning delay for the 
arterial phase was approximately 25 seconds (range, 
20–30 seconds). Portal venous phase and equilibrium 
phase imaging was performed for 60 and 180 
seconds, respectively, after injection of contrast 
medium. One-hour delayed phase images were 
obtained with the VIBE sequence.
Image Analysis
Retrospective image analysis was performed 
independently by two abdominal imagers (15 and 
8 years of radiology experience). The readers were 
informed that the patients had undergone liver 
transplantation and had explant pathologic 
correlation but were blinded to the pathologic 
results. All MR images were reviewed on a PACS 
workstation (Marosis, Marotech). The cases were 
randomly listed on a PACS by one observer. Each 
observer recorded the number and sizes of the 
focal lesions, and all lesions were recorded on a 
liver map. Lesion size was estimated on transverse 
MR images by measurement of the maximum 
diameter with an electronic ruler.
To promote objectivity in image interpretation, 
criteria for HCC were provided to the two radiol-
ogists. Nodules exhibiting enhancement during 
the hepatic arterial phase and lacking portal 
venous supply during the portal venous or equi-
librium phase were regarded as HCC nodules [4, 
34–36]. Nodules exhibiting enhancement during 
the hepatic arterial phase and hypointensity on the 
1-hour delayed phase images were also regarded 
as HCC [37]. A hypointense lesion on dynamic 
sequences and delayed images with a signal 
intensity higher than that of adjacent liver 
parenchyma but lower than that of CSF or 
gallbladder on T2-weighted turbo spin-echo 
sequences also was regarded as HCC [38, 39]. In 
addition, a nodule with hyper intensity on T1-
weighted images and with iso intensity or hypo-
intensity during both phases of dynamic study or 
isointensity or hypointensity on T2-weighted 
images was regarded as a dysplastic nodule [40]. 
Nodules that appeared only during the hepatic 
arterial phase and that had no patho logic correlate 
were defined as nonneoplastic arterial hyper-
vascular lesions.
In cases of false-negative or false-positive 
findings on gadobenate dimeglumine–enhanced 
MR images, the images were reanalyzed after 
retrospective review by the same observers to 
determine the causes of the misinterpretations 
with regard to the size of the HCC nodule and 
lesion size as measured on MR images. In false-
positive cases, lesions that became enhanced on 
arterial phase MR images without corresponding 
pathologic findings, including HCC, dysplastic 
nodule, and regenerative nodule, were regarded 
as nonneoplastic arterial hypervascular lesions.
Reference Standard
As a preoperative evaluation, all imaging 
studies, including CT and MR images, were inter-
preted for HCC burden by consensus of the same 
two gastrointestinal radiologists before liver trans-
plantation, and the pathologist was notified by 
written report regarding all suspected HCC lesions. 
The sonographic information was transferred to the 
two radiologists for tumor burden evaluation.
Gross and histologic analyses of all explanted 
livers were performed by a hepatobiliary pathol-
ogist with 25 years of experience. The presence or 
absence of all lesions identified at preoperative 
interpretation of the images was determined 
histologically on a lesion-by-lesion basis. In 
addition, all other visible nodules on the gross 
specimens that were distinct from the surrounding 
liver tissue also were evaluated histologically. All 
explanted livers were initially sectioned at 5-mm 
or thinner intervals in the sagittal plane. If an 
imaged lesion was not found in the explant, 
representative histologic sections were obtained 
from the region of the liver that best corresponded 
to the lesion location at imaging. For patients with 
no lesions detected at imaging, the pathologic 
specimens were carefully reviewed for the pre-
sence of HCC. The liver slices were photographed, 
and all lesions other than regenerative nodules 
were sampled for histologic examination. Ac-
cording to the diagnostic criteria of the Inter-
national Working Party [41], for nodular hepa-
tocellular lesions, the routinely H and E–stained 
slices from the nodules were classified as follows: 
regenerative nodule; dysplastic nodule, low grade; 
dysplastic nodule, high grade; small HCC (< 2 
cm); or HCC (> 2 cm).
In most cases, a radiologist was not present dur-
ing sectioning of the explanted livers. Dis crepancy 
was minimized by active commun ication between 
the radiologists and the patholo gist regarding the 
multi planar reconstruction present ation of the 
axial images to guide explant sectioning.
Statistical Analysis
Fisher’s exact test was performed to determine 
whether there was a difference in the numbers of 
patients in the included and excluded populations 
in this study. Interobserver variability for detection 
of hepatic nodules was evaluated with nonweighted 
binary kappa statistics. A kappa value of 0.01–0.20 
was classified as minor agreement; 0.21–0.40, 
fair; 0.41–0.60, moderate; 0.61–0.80, high; and 
0.81–1.00, excellent. To evaluate HCC burden, the 
respective sensitivities and positive predictive 
values for the two observers were calculated. The 
sensitivity of HCC detection for lesions larger 
than 2 cm, 1–2 cm, and less than 1 cm in diameter 
and for all lesions was calculated on a per-lesion 
basis. Sensitivity and specificity for the diagnosis 
of HCC also were evaluated. Fisher’s exact test 
was performed to determine whether there was a 
detection difference between HCCs 1 cm or larger 
and those smaller than 1 cm in diameter. Fisher’s 
exact test also was used to evaluate the differences 
in causes of false-positive results according to 
lesion size measured on MR images (≥ 1 cm vs < 1 
cm). A value of p < 0.05 was considered to indicate 
a statistically significant difference. Statistical an-
al yses were performed with the MedCalc program 
(version 9.1.0.1, MedCalc Software).
Results
Pathologic Findings
Twenty-three of the 47 patients in the study 
had 41 HCC nodules (10 patients had one 
lesion; nine, two lesions; three, three lesions; 
and one, four lesions). The mean nodule di-
ameter was 2.2 cm (range, 0.3–6.5 cm). HCC 
differentiation was good in four cases, moderate 
in 36 cases, and poor in one case (Table 2). 
A total of 30 non-HCC nodules were identi-
fied and consisted of 26 dysplastic nodules 
(mean diameter, 0.9 cm; range, 0.5–1.7 cm), 
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two regenerative nodules (0.5 and 0.8 cm), 
one biliary adenoma (0.6 cm), and one he-
mangioma (2.2 cm), which had typical find-
ings on MR images.
Forty-seven of the 66 patients excluded 
from this study were older than 18 years. 
Twelve of those patients had 20 HCC nod-
ules: seven had one lesion; three, two le-
sions; one patient, three lesions; and one, 
four lesions. The mean diameter of these 
nodules was 2.5 cm (range, 0.8–5.3 cm). 
The excluded group had a lower prevalence 
of HCC than did the patients included in the 
study (p = 0.032).
TABLE 2: Size and Differentiation of 
Hepatocellular Carcinoma 
Nodules (n = 41)
Size and Differentiation No.













Note—NA = not available.
TABLE 3: Sensitivity and Positive Predictive Value in Detection of Hepatocellular 
Carcinoma with Gadobenate Dimeglumine–Enhanced MRI 
Characteristic Observer 1 Observer 2
Sensitivity
Total 85 (35/41) 80 (33/41)
> 2 cm 100 (16/16) 100 (16/16)
1–2 cm 89 (16/18) 83 (15/18)
≥ 1 cm 94 (32/34) 91 (31/34)
< 1 cm 43 (3/7) 29 (2/7)
Positive predictive value 66 (35/53) 65 (34/52)
Note—Values are percentages with corresponding counts in parentheses.
D
A
Fig. 1—55-year-old man with macronodular cirrhosis 
and 1.3-cm-diameter hepatocellular carcinoma in 
liver segment 7.
A, Unenhanced axial T1-weighted volumetric 
interpolated breath-hold examination (VIBE) image 
(TR/TE, 3.6/1.7; flip angle, 12°) shows no liver lesion.
B, Hepatic arterial phase gadobenate dimeglumine–
enhanced axial T1-weighted VIBE image (3.6/1.7; flip 
angle, 12°) shows enhancing nodule (arrow) in liver 
segment 7.
C, Portal venous phase gadobenate dimeglumine–
enhanced axial T1-weighted VIBE image (3.6/1.7; flip 
angle, 12°) shows no liver lesion.
D, Delayed axial T1-weighted VIBE image (3.6/1.7; 
flip angle, 12°) obtained 1 hour after gadobenate 
dimeglumine administration shows no liver lesion.
E, Photomicrograph of sagittal section of pathologic 
specimen shows 1.3-cm-diameter hepatocellular 
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Image Analysis
Interobserver variability between the two 
readers suggested excellent agreement (κ = 
0.815 ± 0.093 [SD]) for detection of hepatic 
nodules. Table 3 shows that for HCC detection, 
observer 1 had a sensitivity of 85% (35 of 41 
HCCs) and a positive predictive value of 66% 
(35 of 53 readings). Observer 2 had a sensitiv-
ity of 80% (33 of 41 HCCs) and a positive pre-
dictive value of 65% (34 of 52 readings).
In terms of sensitivity, the two observers 
had significant differences (p = 0.004, p = 
0.001) between detection of HCCs 1 cm or 
larger (94% and 91%) and those smaller than 
1 cm (43% and 29%) (Fig. 1). The two and 
three HCC nodules 1 cm or larger missed by 
observers 1 and 2 on gadobenate dimeglu-
mine–enhanced MR images were pathologi-
cally confirmed to be well-differentiated 
HCC (Table 3).
All MRI lesions measuring more than 2 cm 
in diameter were determined to be HCC. Ta-
ble 4 summarizes the causes of all false-posi-
tive diagnoses of lesions measuring 2 cm in 
diameter or smaller on MRI. Nonneoplastic 
arterial hypervascular lesions more often 
caused false-positive MRI diagnoses of le-
sions measuring less than 1 cm in diameter 
(80%, 12 of 15 readings; 86%, 12 of 14 read-
ings) than of lesions 1 cm in diameter or larger 
(0%, none of three readings; 25%, one of four 
readings) with statistically significant differ-
ences (p = 0.025, p = 0.044) for the two ob-
servers (Figs. 2 and 3). For both observers, the 
false-positive MRI lesions measuring 1 cm in 
diameter or greater were dysplastic nodules; 
three high-grade dysplastic nodules 1 cm in 
diameter or larger were interpreted as HCC 
nodules by both observers. Both observers’ 
readings indicated that the sensitivity for the 
diagnosis of HCC was 87% (20 of 23 patients) 
and the specificity was 79% (19 of 24).
Discussion
Our study results show that gadobenate di-
meglumine–enhanced MRI had a sensitivity 
of 80–85% and positive predictive value of 
65–66% in the detection of HCC nodules 
when used together with explant pathologic 
correlation. In addition, gadobenate dimeglu-
mine–enhanced MRI had a higher sensitivity 
for detection of HCC nodules 1 cm in diame-
ter or larger (91–94%) than for those smaller 
than 1 cm in diameter (29–43%), a significant 
difference (p < 0.05). The performance gain 
with gadobenate dimeglumine–enhanced MRI 
was excellent for nodules measuring 1 cm or 
more in diameter. We attribute this MRI per-
formance to use of a modified 3D gradient-
echo technique and the almost twofold greater 
T1 relaxivity of gadobenate dimeglumine rel-
ative to conventional gadolinium-based agents 
and to the excellent intrinsic soft-tissue con-
trast enhancement of MRI [8, 18, 20, 42–45].
The fat-suppressed 3D gradient-echo MR 
sequence (VIBE) we used for dynamic MRI 
allowed shorter scan times and use of thinner 
(1–3-mm) sections without image degradation 
through use of asymmetric k-space sampling 
and interpolation [42–45]. In our study, how-
ever, gadobenate dimeglumine–enhanced MRI 
had only limited utility in the detection of 
HCC nodules smaller than 1 cm in diameter 
and well-differentiated lesions, which often 
appear hypovascular because of insufficient 
arterial neovascularization in the setting of a 
decreased portal supply. A previous study 
[46] showed relatively high sensitivity (82– 
88%) in the detection of HCC nodules 1 cm in 
diameter or smaller with gadobenate dimeglu-
mine–enhanced MRI compared with our 
finding (29–43% sensitivity). However, the 
TABLE 4: False-Positive Findings in 
Detection of Hepatocellular 
Carcinoma on Gadobenate 
Dimeglumine–Enhanced 
MRI
Finding Observer 1 Observer 2
1–2 cm









Regenerative nodule 1 0
Total 18 18
Note—NA = not available.
A
Fig. 2—47-year-old man with macronodular cirrhosis.
A, Unenhanced axial T1-weighted volumetric interpolated breath-hold examination (VIBE) image (TR/TE, 3.6/1.7; flip angle, 12°) shows no liver lesion.
B, Hepatic artery phase gadobenate dimeglumine–enhanced axial T1-weighted VIBE image (3.6/1.7; flip angle, 12°) shows enhancing 9-mm-diameter lesion (arrow) in 
liver segment 5. No nodule was identified at pathologic examination. Lesion was considered nonneoplastic arterial hypervascular lesion.
C, Portal venous phase gadobenate dimeglumine–enhanced axial T1-weighted VIBE image (3.6/1.7; flip angle, 12°) shows subtle enhancing lesion (arrow) in liver  
segment 5.
CB
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larger. Nonneoplastic arterial hypervascular 
lesions were the major cause of false-positive 
diagnoses of lesions smaller than 1 cm in di-
ameter (80–86%) and dysplastic nodules the 
cause in the case of lesions 1 cm in diameter 
or larger (85–100%). The results of this study 
partially correlate with those of a study by 
Holland et al. [47], who reported that 60% of 
nonneoplastic arterial hypervascular lesions 
were smaller than 1 cm in diameter.
In our study, the quality of delayed phase 
images was poor owing to weak enhancement 
of hepatic parenchyma related to poor hepato-
cyte function in advanced cirrhosis. Therefore, 
the diagnostic value of delayed phase imaging 
in characterization and detection of hepatocel-
lular nodules in cirrhotic liver was limited. 
These findings are similar to those in a study 
by Grazioli et al. [21], in which positive corre-
lation (Spearman’s correlation, 0.359) was ob-
served between the degree of liver failure and 
worsening of lesion-to-liver contrast-to-noise 
ratio on delayed phase images.
At our institution, patients waiting for liv-
er transplantation usually underwent follow-
up with dynamic liver CT, and gadobenate 
dimeglumine–enhanced MRI was used for 
those who had suspicious nodules on CT im-
ages or could not undergo dynamic liver CT 
because of a medial problem. The 47 adult 
patients excluded from this study did not un-
dergo gadobenate dimeglumine–enhanced 
MRI because of definite hypervascular le-
sions on CT images and an increased 
α-fetoprotein level in some patients and no 
abnormality on CT in others. Thus only 12 
patients had histopathologic proof of HCC, 
and four of these patients were reported to 
have no lesions suspected of being HCC on 
CT. Finally, the main population of this study 
consisted of patients with suspicious nodules 
on dynamic liver CT, which might have led 
to selection bias that increased the sensitivity 
of HCC detection.
A radiologist was not present at the time of 
liver explant sectioning, and the reference 
standard was the written report by the pathol-
ogist because this study was performed retro-
spectively. At our institution, however, liver 
specimens are evaluated under strict protocol, 
which is reflected by the relatively low sensi-
tivity for HCC nodules smaller than 1 cm in 
this study compared with previous studies.
Apart from the intrinsic limits of any ret-
rospective study, our study had several limi-
tations. First, that the imaging plane (trans-
verse) differed from the pathologic plane 
(sagittal) potentially complicated lesion 
reference standard in that study was limited 
liver resection, image-guided biopsy, or iodized 
oil CT combined with elevated α-fetoprotein 
level, and such an approach might hide ob-
server bias and tend to lead to underestima-
tion of extent of disease [4].
In terms of positive predictive value, our 
study showed lower performance (65–66%) 
than previous studies (85–96%) [8, 46]. It 
has been reported [8] that the combination of 
the higher enhancing capability of gado-
benate dimeglumine and the VIBE sequence 
tends to maximize sensitivity in detection of 
enhancing hepatic lesions regardless of the 
presence of an arterioportal shunt or of a true 
hypervascular liver lesion. Therefore, in our 
study, the advanced cirrhotic state of the liv-
ers was associated with foci of nonmalignant 
hypervascularity, including nonneoplastic 
arterial hypervascular lesions and enhancing 
dysplastic or regenerative nodules, thereby 
accounting for the false-positive findings 
[32, 36]. In addition in our study, the major 
causes of false-positive diagnoses of lesions 
of smaller than 1 cm on MRI were different 
from those for lesions 1 cm in diameter or 
A
C
Fig. 3—38-year-old man with macronodular cirrhosis and 8-mm-diameter dysplastic nodule in liver segment 4.
A, Unenhanced axial T1-weighted volumetric interpolated breath-hold examination (VIBE) image (TR/TE, 
3.6/1.7; flip angle, 12°) shows no liver lesion.
B, Hepatic arterial phase gadobenate dimeglumine–enhanced axial T1-weighted VIBE image (3.6/1.7; flip angle, 
12°) shows enhancing mass (arrow) in liver segment 4.
C, Portal venous phase gadobenate dimeglumine–enhanced axial T1-weighted VIBE image (3.6/1.7; flip angle, 
12°) shows no liver lesion.
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matching and localization. Although we 
made an effort to match the in vivo MR im-
ages with the whole explanted livers, precise 
lesion-by-lesion correlation was extremely 
difficult because of the difference between 
the pathologic and imaging planes. Second, 
many patients included in our study had ad-
vanced cirrhosis, which might have de-
creased the detection and characterization 
performance of gadobenate dimeglumine–
enhanced MRI for focal liver lesions.
Our study results show that dynamic gad-
obenate dimeglumine–enhanced MRI has a 
sensitivity of 80–85% and positive predictive 
value of 65–66% in the detection of HCC 
nodules with explant pathologic correlation. 
For lesions smaller than 1 cm in diameter, 
however, this technique has limitations for 
detection and characterization, accounting 
for most of our false-negative and false-posi-
tive findings.
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